Mycosis Fungoides
📧 Sign up to get email alerts when something new happens for Mycosis Fungoides.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-12-31Clinical Trial Update: Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides [Phase 2]
Phase 2 trial results for Total Skin Electron Beam Therapy in stage IB-IIIA mycosis fungoides were posted.
-
FDA label_change · 2015-10-29FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride), resulting in labeling updates for the product.
-
FDA approval · 2015-09-14FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS research · 2015-05-22Clinical Trial Update: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating UVA/UVB light therapy for inflammatory skin conditions sponsored by the University of Michigan; the stud…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Effect of Denileukin Diftitox on Immune System in CTCL Patients
This completed trial update reports on the effects of denileukin diftitox on the immune system in patients with cutaneous T-cell lymphoma, i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-03-23Clinical Trial Update: O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial assessed the combination of O6-Benzylguanine with topical Carmustine in patients with early-stage cutaneous T-cell lymphom…
-
FDA approval · 2014-12-02FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for Targretin (bexarotene) submitted by Bausch Health US, LLC.
-
FDA approval · 2014-10-13FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc.
-
FDA approval · 2014-08-12FDA Approved: BEXAROTENE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's generic bexarotene for use in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome.
-
CLINICAL_TRIALS trial_result · 2014-08-01Clinical Trial Update: CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas [Phase 1, Phase 2]
A Phase 1/2 study evaluating CPG 7909 with local radiotherapy for recurrent low-grade lymphomas has completed, with results posted in 2014.
-
FDA approval · 2014-07-09FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc.
-
FDA approval · 2014-07-08FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
The FDA approved a supplemental application for Valchlor (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc., supporting …
-
CLINICAL_TRIALS research · 2014-05-28Clinical Trial Update: In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
An in vitro study from the University of Pittsburgh evaluates immune responses in cutaneous T-cell lymphoma, including Sézary syndrome and m…
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides [Phase 2]
This entry provides an update on a Phase 2 trial of combination chemotherapy for advanced or recurrent mycosis fungoides. Mycosis fungoides …
-
FDA approval · 2013-08-23FDA Approved: VALCHLOR — Original Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved VALCHLOR (mechlorethamine hydrochloride) gel in an original application for the treatment of mycosis fungoides, a type of cutan…
-
FDA approval · 2013-07-22FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
FDA approval · 2013-04-24FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Zolinza (vorinostat) filed by Merck. The action updates the labeling and may reflect changes…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas [Phase 1]
This Phase 1 trial evaluated entinostat (MS-275) plus isotretinoin in adults with metastatic or advanced solid tumors or various lymphomas; …
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating 506U78 for recurrent or refractory cutaneous T-cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: 506U78 in Treating Patients With Lymphoma [Phase 2]
Phase 2 clinical trial update on the agent 506U78 for various lymphomas; the study has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 trial evaluating interleukin-12 and interleukin-2 in patients with mycosis fungoides and Sezary syndrome. The study was terminated…
-
CLINICAL_TRIALS trial_result · 2012-12-04Clinical Trial Update: Interleukin-2 in Treating Patients With Mycosis Fungoides [Phase 1]
Phase 1 trial evaluating interleukin-2 in patients with mycosis fungoides; the study has completed.
-
CLINICAL_TRIALS trial_result · 2012-10-31Clinical Trial Update: Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating the safety and efficacy of Nitrogen Mustard (mechlorethamine) for treating Mycosis fungoides has completed with res…
-
CLINICAL_TRIALS research · 2012-08-22Clinical Trial Update: Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma [NA]
The update discusses evaluating killer immunoglobulin-like receptor transcripts as a diagnostic approach for epidermotropic cutaneous T-cell…
-
CLINICAL_TRIALS trial_result · 2012-08-09Clinical Trial Update: An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides [Phase 2]
An open-label Phase 2 study evaluating the safety and efficacy of a 0.04% topical mechlorethamine formulation in Mycosis fungoides has compl…